1. Home
  2. NRSN vs OSRH Comparison

NRSN vs OSRH Comparison

Compare NRSN & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd.

N/A

Current Price

$0.43

Market Cap

17.7M

Sector

Health Care

ML Signal

N/A

Logo OSR Holdings Inc.

OSRH

OSR Holdings Inc.

N/A

Current Price

$0.62

Market Cap

17.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NRSN
OSRH
Founded
2017
N/A
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.7M
17.9M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
NRSN
OSRH
Price
$0.43
$0.62
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
224.1K
577.0K
Earning Date
03-31-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,905,805.00
Revenue This Year
N/A
$9.30
Revenue Next Year
$583.67
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$0.25
52 Week High
$1.33
$1.24

Technical Indicators

Market Signals
Indicator
NRSN
OSRH
Relative Strength Index (RSI) 29.21 68.31
Support Level $0.39 $0.57
Resistance Level $0.74 $0.73
Average True Range (ATR) 0.07 0.07
MACD -0.00 0.00
Stochastic Oscillator 26.33 77.87

Price Performance

Historical Comparison
NRSN
OSRH

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

About OSRH OSR Holdings Inc.

OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.

Share on Social Networks: